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The objective of this study was to investigate the therapeutic results of arterial injection therapy via the superficial temporal artery for
134 cases of stages III and IV (M0) oral cavity cancer retrospectively, and to clarify the prognostic factors. We administered intra-
arterial chemoradiotherapy by continuous infusion of carboplatin in 65 cases from January 1993 to July 2002. Systemic chemotherapy
was performed on 26 cases at the same time. We administered intra-arterial chemoradiotherapy by cisplatin with sodium
thiosulphate in 69 cases from October 2002 to December 2006. Systemic chemotherapy was performed on 48 cases at the same
time. The 3-year local control rate was 68.6% (T2-3: 77.9%; T4: 51.3%), and the 3-year survival rate was 53.9% (stage III: 62.9%; stage
IV: 45.3%). Regarding the results of multivariate analysis of survival rates, age (o65), selective intra-arterial infusion, and the use of
cisplatin as an agent for intra-arterial infusion were significant factors. The therapeutic results of intra-arterial chemoradiotherapy via
the superficial temporal artery were not inferior to the results of surgery. In particular, the results of arterial injection therapy by
cisplatin with sodium thiosulphate were excellent, so we believe that it will be a new therapy for advanced oral cavity cancer.
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As locally advanced oral cavity cancer is difficult to control by
radiotherapy, surgery remains the most effective curative therapy
(Poulsen et al, 1996). In this case, an extended surgery markedly
reduces the quality of life, thus affecting the patient’s social life.
Therefore, the development of effective non-resection therapy is
extremely important.
In 1992, we started chemoradiation therapy, in which continuous
arterial infusion therapy with carboplatin was combined with
radiotherapy, by selectively inserting a catheter into the target artery
through the superficial temporal artery in patients with locally
advanced head and neck cancer (Fuwa et al,2 0 0 0 ) .W es t a r t e d
therapy in two courses of systemic chemotherapy combined with
intra-arterial chemoradiotherapy by continuous intra-arterial infu-
sion of carboplatin and radiation therapy, in an effort to control
metastasis in cervical lymph nodes and distant metastasis in 1997
(Fuwa et al, 2007). Furthermore, we changed the agent for intra-
arterial infusion from carboplatin to cisplatin in an effort to improve
the local control rate in October 2002. This is an improved
technique of the Robbins et al method (Robbins et al, 1994, 2000),
whereby an infusion dose of cisplatin was increased by infusing
sodium thiosulphate, which is a neutralising agent of cisplatin, from
a vein at the time of intra-arterial infusion of cisplatin.
In this article, we analyse the therapeutic results of 134 cases of
stages III and IV (M0) oral cavity cancer retrospectively to
investigate the prognostic factors, and we inspect the effectiveness
of arterial injection therapy via the superficial temporal artery for
cases of advanced oral cavity cancer.
MATERIALS AND METHODS
Patient selection criteria
The subjects met the following criteria: (1) the pathology is
squamous cell carcinoma; (2) stage III or higher oral cavity cancer
(except carcinoma of the base of tongue) without distant
metastasis according to the TNM staging published in 2002; (3)
patients in whom the performance status (PS) was evaluated as
0–3 according to the classification described by the Eastern
Cooperative Oncology Group; (4) ages ranging from 20 to 89 years;
(5) the bone marrow function was maintained (leukocyte count:
3000mm
 2 or more, platelet count: 100000mm
 2 or more); (6)
patients without severe liver, kidney, heart, or lung dysfunction;
(7) untreated patients; (8) patients without active double cancer at
the start of treatment, and who had not previously undergone
radiotherapy in the head and neck region; and (9) patients from
whom written informed consent was obtained.
Treatment schedule, administration of the agent
The treatment schedule was divided into four groups (Figure 1).
Continuous arterial injection of carboplatin was performed using a
portable electrical pump for 6 weeks in Group 1. Using Calvert’s
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sformula, the total dose of carboplatin was established as six- to
eight-fold the area under the plasma concentration–time curve
(AUC) according to both the kidney function and PS.
As mentioned above, we started a new chemoradiation therapy
in which continuous arterial infusion therapy with carboplatin was
combined with two courses of systemic chemotherapy with 5-
fluorouracil and nedaplatin in order to control the neck lymph
nodes and distant metastases (Group 2) in 1997. Carboplatin (total
dose: AUC 6) was administered continuously in the latter half of
radiotherapy after the end of the second course of systemic
chemotherapy. The regimen of systemic chemotherapy consisted
of continuous intravenous injection of 5-fluorouracil at
700mgm
 2 for 5 days (from Day 1 until Day 5) and intravenous
drip of nedaplatin at 120mgm
 2 over 6h on Day 6.
To further improve the local control, we modified the procedure
described by Robbins et al from October 2002. The dose of
cisplatin was established as 20mgm
 2 when the catheter was
inserted into the selected artery, and 30mgm
 2 when the catheter
was inserted into the external carotid artery. During the arterial
injection of cisplatin, a cisplatin-neutralising agent, sodium
thiosulphate, at 8–10gm
 2 was intravenously administered over 7h.
When inserting catheters into arteries on both sides, we set the
amount of the infused dose of CDDP up to 40mgm
 2 in total per
week; and to distribute the agent appropriately, we decided the
amount of agent distributed from the findings of the MRI.
In patients who were not eligible for systemic chemotherapy,
including elderly patients (X75years) and those with a poor PS
score, cisplatin arterial injection chemotherapy was repeated six to
seven times in combination with radiotherapy at 60–70Gy (Group 3).
In patients in whom systemic chemotherapy was possible,
alternating therapy involving systemic chemotherapy and
radiation therapy was performed. Arterial injection therapy was
repeated four to five times after the end of the second course of
systemic chemotherapy (Group 4). The regimen of systemic
chemotherapy consisted of the continuous intravenous injection
of 5-fluorouracil at 700mgm
 2 for 5 days (from Day 1 until Day 5)
and intravenous drip of cisplatin at 85mgm
 2 over 24h on Day 6.
In patients with a poor renal function (24-h creatinine clearance
was 60mlmin
 1 or less), nedaplatin at 100mgm
 2 was adminis-
tered in place of cisplatin.
Radiation therapy
Radiotherapy was performed five times a week by irradiating 1.8–
2Gy of photon beam in a fraction using a 6MV linear accelerator.
The initial irradiation (irradiation method A) was performed five
times a week for 4 weeks at a radiation dose of 1.8–2Gy (total
dose: 36–40Gy). The latter half of irradiation (irradiation method
B) was performed five times a week for 3 weeks at a radiation dose
of 2Gy (total dose: 26–30Gy) (AþB: 66Gy).
In the irradiation method A, using the bilateral opposing portal
irradiation method, 36–40Gy in 20 fractions was irradiated
between the primary lesion, the middle cervical lymph nodes,
and a 2cm safety margin, whereas 36–40Gy of photon beam was
irradiated between the lower cervical region and the supraclavi-
cular fossa using the anterior single irradiation method.
In irradiation method B, an area involving the tumour site on
the initial consultation and a 1cm safety margin was established as
the planned target volume (PTV). The radiation dose for the spinal
cord was established as 40Gy or less. In patients with tongue or
oral floor cancer in whom brachytherapy was possible, external
irradiation at a radiation dose of approximately 50Gy or less was
combined with brachytherapy using a Cs needle or Au grain.
Arterial injection therapy
As previously reported (Fuwa et al, 2000), the anterior ear on the
affected side was incised under local anaesthesia to expose the
superficial temporal artery. During fluoroscopy, a thin catheter
was selectively inserted into the selected artery. When the lesion
involved the contralateral side beyond the median line, another
catheter was inserted in the contralateral side for bilateral arterial
injection. The target artery was the lingual artery in carcinoma of
the tongue, the facial artery in carcinomas of the floor of mouth,
the buccal mucosa, and lower gingiva, and the maxillary artery in
carcinomas of the hard palate and upper gingiva.
When the tumour involved beyond the perfusion area by
selected arterial injection, or when severe arteriosclerosis made the
selective insertion of a catheter into the selected artery difficult, a
catheter was placed in the external carotid artery.
We confirmed that the extent of arterial injection covered the
tumour by a pigment, angiography, and MRI from 2001, in which
an extremely low dose of contrast medium for MRI was slowly
infused via a catheter for arterial injection.
This clinical trial was approved by the Ethics Committee of
Aichi Cancer Center Hospital.
Patient assessments
The treatment response was evaluated based on the MRI. The
subjects consulted the outpatient clinic at 1-month intervals for 1
year after the end of treatment, at 2- to 3-month intervals in the
second and third years of follow-up, and at 3–5 month intervals
after 3 years of follow-up. Follow-up MRI was performed at 4- to
6-month intervals for 2 years after the end of treatment, and at
6- to 8-month intervals thereafter. Chest X-rays were performed
at 6- to 8-month intervals, and liver CT or echogram was
performed every year until 3 years after the end of treatment.
Group 1: systemic chemotherapy (–)
Group 2: systemic chemotherapy (+)
Ext. RT: method A
Ext. RT
method B
CT CT
CBDCA continuous infusion (AUC 6–8)
CBDCA continuous infusion (AUC 6)
(brachy) Ext. RT
method A
Ext. RT: method B (brachy)
Group 3: systemic chemotherapy (–)
Group 4:  systemic chemotherapy (+)
CT CT (brachy)
CDDP 20–30 mg m–2 × 6–7+STS
Weekly CDDP 20–30 mg m–2 × 4–5+STS
Ext. RT: method A Ext. RT: method B (brachy)
Ext. RT
method A
Ext. RT
method B
Figure 1 Scheme of the therapy. CT, chemotherapy; Ext RT, external
beam radiation therapy. Method A: wide field irradiation, 36–40 Gy/20
fraction. Method B: reduced field irradiation, 26–30 Gy/15 fraction. Brachy,
brachytherapy. Alternating therapy involving systemic chemotherapy and
radiation therapy is performed. Intra-arterial chemotherapy is initiated after
the end of the second course of systemic chemotherapy in the Groups 2
and 4.
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sRegarding the factors that affect the local control rate, we
investigated the age (less than 65 years of age vs 65 years of age and
over), the T stage (T2, T3 vs T4), the site (tongue vs oral cavity
except tongue), the presence of systemic chemotherapy (Groups 1,
3 vs Groups 2, 4), the difference between selective intra-arterial
infusion and non-selective intra-arterial infusion (external carotid
artery), and the difference between agents for intra-arterial
infusion (carboplatin vs cisplatin). Regarding the factors that
affect the survival rate, we investigated N stage (N0, 1 vs N2, 3),
clinical stage (III vs IV), and PS (0, 1 vs 2, 3) in addition to the six
factors noted above.
We used the Kaplan–Meier method for survival and local
recurrence-free analyses and the log-rank test to determine
whether any significant differences existed between different
patients in terms of end points. Survival and local recurrence-
free rates were calculated (as of April 1, 2007 or the date of the last
medical examination) from the start of treatment to the date of the
event.
The Cox regression model was used to perform a multivariate
analysis.
RESULTS
Patient population
The subjects consisted of 136 patients with locally advanced oral
cavity cancer who underwent intra-arterial chemotherapy com-
bined with radiation therapy between January 1993 and December
2006 (Table 1). Because the amount of agent for intra-arterial
infusion in two cases out of 136 was less than 50% of the scheduled
amount, we performed an analysis with 134 cases infused with 50%
or more of the prescribed amount.
Table 2 shows the TNM staging, age, and PS among the four
groups. The median age of Groups 1 and 3 was 17 years older than
that of the Groups 2 and 4. The percentage of good PS patients was
higher in the Groups 2 and 4. Written informed consent was
obtained from all the patients.
Follow-up studies were sufficiently performed in the 131
patients except in three patients as of April 2007. The median
follow-up duration for patients who were alive was 45.4 months
(range: 5–168 months).
Treatment delivery
The selected arteries consisted of the lingual artery in 52 patients,
the bilateral lingual arteries in 12 patients, the facial artery in 12
patients, the faciolingual trunk in 4 patients, the maxillary artery in
1 patient, the external carotid artery in 48 patients, the external
carotid artery and contralateral lingual artery in 3 patients, and the
external carotid artery and contralateral facial artery in 1 patient.
During the treatment course, the route was changed from the
lingual artery to the external carotid artery in two patients. The
total dose of carboplatin ranged from 240 to 800mg, with a median
of 430mg. The total dose of cisplatin ranged from 40 to 390mg,
with a median of 120mg. In the arterial injections of carboplatin,
87% of the cases were administered the scheduled quantities of
carboplatin, whereas 5% of the cases were administered 50% or
less of the scheduled quantities of carboplatin. In the arterial
injections of cisplatin, 75% of the cases were administered the
scheduled quantities of cisplatin, whereas 5% were administered
50% or less of the scheduled quantities of cisplatin.
Of the patients, 74 (55.2%) patients received systemic
chemotherapy. The number of chemotherapy courses was one in
9 patients, and two in 65 (87.8%) patients.
The radiation dose ranged from 27 to 78Gy, with a median of
63Gy. Brachytherapy was performed in 41 (30.6%) patients;
interstitial irradiation using a Cs needle was performed on 14
patients, and interstitial irradiation using Au grain was performed
on 27 patients.
Treatment results
A complete response was achieved in 109 patients, and a partial
response in 25 patients. A relapse was detected in 65 patients:
primary site, 36 patients; cervical lymph node, 19 patients; primary
site and cervical lymph node, 2 patients; primary site and distant
metastasis, 1 patient; cervical lymph node and distant metastasis, 2
patients; distant metastasis, 5 patients. The 3-year local (primary
site) recurrence-free rate of all patients was 68.6% (95% confidence
interval (CI): 60.6–77.7%) (Figure 2A). Cumulative local recur-
rence-free rate of T2-3 and T4 patients at 3 years were 77.9% (95%
CI: 69.1–87.9%) and 51.3% (95% CI: 37.5–70.2%), respectively
(Figure 2B).
Of the patients demonstrating a relapse, salvage surgery was
performed in 15 patients, intra-arterial chemoradiation in 9
patients, intra-arterial chemotherapy in 3 patients, chemoradiation
Table 1 Characteristics of 134 patients with squamous cell carcinoma of
the oral cavity
Age (years)
Median 67
Range 25–89
Gender
Male 89
Female 45
Performance status (ECOG)
02 6
19 3
21 1
34
TNM (2002) T stage
T1 0
T2 16
T3 67
T4a 49
T4b 2
TNM (2002) N stage
N0 61
N1 34
N2a 1
N2b 28
N2c 6
N3 4
Stage
III 63
IV A 67
IV B 4
Primary tumour site
Tongue 88
Lower gingiva 16
Floor of the mouth 14
Buccal mucosa 12
Upper gingiva 3
Hard palate 1
Reasons not performing surgery
Refusal 78
Old age 27
Poor performance status 10
Poor cardio-pulmonary function 10
Inoperable advanced lesion 9
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stherapy in 3 patients, radiation therapy in 5 patients, and
chemotherapy in 1 patient. Of these 36 patients, 9 patients had
successful salvage (surgery in 5 patients, intra-arterial chemo-
radiation in 3 patients, chemoradiation therapy in 1 patient),
becoming disease-free after the procedure.
At the time of analysis, 65 patients had died, 66 patients were
still alive, and 3 patients had been lost to the follow-up. In the 65
patients who had died, the cause of death was oral cavity cancer in
45, other diseases in 18, and treatment-related complication in 2.
The 3-year overall survival of all patients was 53.9% (95% CI:
45.4–64.0%) (Figure 3A). Cumulative survival rates of stages III
and IV patients at 3 years were 62.9% (95% CI: 51.4–77.0%) and
45.3% (95% CI: 33.9–60.5%), respectively (Figure 3B).
Factors of survival and local recurrence
In a univariate analysis, T factor, the selected artery, and the site
were found to have a significant impact on local recurrence,
whereas systemic chemotherapy and difference of IA chemotherapy
had only a marginal significance. In a multivariate analysis,
T factor and difference of IA chemotherapy were of borderline
significance (Table 3).
In a univariate analysis, age, systemic chemotherapy, and
difference of IA chemotherapy were found to have a significant
impact on survival. In a multivariate analysis, age, difference of IA
chemotherapy, and selected artery were found to have a significant
impact on survival, whereas systemic chemotherapy was not a
significant factor (Table 4).
Acute toxicity
Acute toxicity is summarised in Table 5. Grade 3 or higher toxic
changes included granulocytopaenia in 60 (45%) patients,
thrombopaenia in 31 (23%) patients, anaemia in 26 (19%) patients,
and mucositis in 15 (11%) patients. There was no significant
difference in the degree of acute toxicity among the four groups.
Table 2 TNM stage, age, and PS among the groups
Group 1
(n¼39)
Group 2
(n¼26)
Group 3
(n¼21)
Group 4
(n¼48)
Stage
III 26 14 5 18
IVA 13 12 14 28
I V B 0022
Age (years)
Median 73 59 77 59
Range 51–90 25–73 62–87 25–73
PS
0 283 1 3
1 2 91 71 43 3
2 6131
3 2011
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Figure 2 Actuarial local (primary site) recurrence-free rate of patients
with advanced squamous cell carcinoma of the oral cavity by Kaplan–Meier
method. (A) Actuarial local (primary site) recurrence-free rate of all
patients. A solid line: local control rate curve. A broken line: 95% CI. (B)
Actuarial local (primary site) recurrence-free rate according to the T stage.
A solid line: T2þT3 cases (n¼83). A broken line: T4 cases (n¼51).
P¼0.00531.
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Figure 3 Actuarial survival rates of patients with advanced squamous cell
carcinoma of the oral cavity by Kaplan–Meier method. (A) Actuarial
survival rates in all 134 patients. A solid line: overall survival curve. A broken
line: 95% CI. (B) Actuarial survival rates according to the stage. A solid line:
stage III cases (n¼63). A broken line: stage IV cases (n¼71). P¼0.117.
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sIn addition, no transient or persistent central nervous complica-
tions were observed. Treatment-related death was confirmed in
two patients. Although tumours in both patients disappeared as a
result of therapy, both patients died of gastrointestinal bleeding.
Chronic toxicity
We studied chronic toxicity in 97 patients who survived more than
12 months after the treatment. Although these 97 patients did not
develop severe problems in their phonation or deglutition function
and were able to eat almost normally, continuous glossalgia was
recognised in one of the patients and analgesic was sometimes
necessary for this patient, and two patients developed osteo-
radionecrosis, which needed surgery.
DISCUSSION
The results of radiotherapy for advanced oral cavity cancer alone
were poor (Decroix and Ghossein, 1981; Horiuchi et al, 1982).
Currently, surgery is the standard treatment (Poulsen et al, 1996).
Several studies have reported arterial injection therapy for oral
cavity cancer; however, the number of patients in such studies
tended to be small, and its usefulness has not yet been clearly
Table 3 Results of the multivariate analysis of prognostic factor on local recurrence-free time based on Cox proportional-hazards model
Selected factor Level Adjusted P-value
a Adjusted HR (95% confidence interval)
T classification T2 or T3 0.0501 1.000 (referent)
T4 2.11 (0.999, 4.45)
Site Tongue 0.684 1.000 (referent)
Oral cavity except tongue 1.16 (0.558, 2.42)
Systemic chemotherapy NO (Group 1 or 3) 0.265 1.000 (referent)
YES (Group 2 or 4) 0.682 (0.347, 1.33)
IA chemotherapy CBDCA 0.0884 1.000 (referent)
CDDP 0.552 (0.278, 1.09)
Artery Selected artery 0.106 1.000 (referent)
External carotid artery 1.76 (0.885, 3.53)
aThe P-value for the log-rank test.
Table 4 Results of the multivariate analysis of prognostic factors on overall survival based on Cox proportional-hazards model
Selected factor Level Adjusted P-value)
a Adjusted HR (95% confidence interval)
Age (year) o65 0.0185* 1.000 (referent)
4¼65 2.05 (1.12, 3.75)
Systemic chemotherapy NO (Group 1 or 3) 0.104 1.000 (referent)
YES (Group 2 or 4) 0.610 (0.336, 1.10)
IA chemotherapy CBDCA 0.0141* 1.000 (referent)
CDDP 0.477 (0.265, 0.861)
Artery Selected artery 0.0290* 1.000 (referent)
External carotid artery 1.74 (1.05, 2.86)
aThe P-value for the Wald’s test. *P-valueo0.05.
Table 5 Toxicity according to the group
Group 1 (n¼39) Group 2 (n¼26) Group 3 (n¼21) Group 4 (n¼48)
Toxicities 0–2 3 4 0–2 3 4 0–2 3 4 0–2 3 4
Haematologic
White blood cell 21 15 3 15 5 6 9 8 4 24 18 6
Granulocyte 22 13 4 15 5 6 11 8 2 26 14 8
Platelet 32 4 3 14 6 6 18 2 1 39 4 5
Haemoglobin 34 4 1 20 6 0 18 3 0 36 10 2
Non-haematologic
Liver 39 0 0 25 1 0 21 0 0 47 1 0
Kidney 39 0 0 26 0 0 21 0 0 48 0 0
Vomiting 39 0 0 26 0 0 21 0 0 46 2 0
Mucocitis 37 2 0 23 3 0 19 2 0 40 8 0
Fever 37 2 0 25 1 0 20 1 0 48 0 0
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sdemonstrated (Hirai et al, 1999; Damascelli et al, 2003; Kovacs,
2004). No randomised controlled trials have yet been performed to
compare the effectiveness of surgery with chemoradiation, and the
usefulness of chemoradiation therapy involving systemic chemo-
therapy thus remains to be clarified.
After surgery, the 5-year survival rate ranged from 27 to 60% of
stage III patients, while it ranged from approximately 12 to 40% of
stage IV patients (Chen et al, 1999; Sessions et al, 2002; Greenberg
et al, 2003; Lo et al, 2003; Gorsky et al, 2004; Liao et al, 2006; Fan
et al, 2007); our results were therefore similar to the results after
surgery. In particular, the results of arterial injection therapy by
cisplatin with sodium thiosulphate were excellent.
Currently, there are two procedures for performing arterial
infusion therapy for head and neck cancer: namely, a procedure in
which a catheter is inserted into the target artery through the
superficial temporal artery, as presented in this study, and a
procedure in which a catheter is inserted into the target artery
through the femoral artery by Seldginger’s procedure (Robbins
et al, 1994, 2000; Balm et al, 2004; Alkureishi et al, 2006). The latter
procedure is simpler than the former procedure, and it facilitates
the administration of anticancer agents into several arteries;
however, drug administration over a long duration is impossible,
and catheter operation-related cranial nerve disorders may some-
times occur. Although Robbins et al reported the incidence of
cranial nerve disorders to be 2–4%, no patient showed a cranial
nerve disorder in our study. While, in his series, the mean age was
56 years, the median age was 67 years in our study. Therefore,
arterial injection therapy in which a catheter is inserted into the
target artery through the superficial temporal artery may therefore
be appropriate for elderly patients, and the drug can thus be
administered over a long duration.
The dose of cisplatin in our study was approximately 1/5 of
that described by Robbins et al. However, the duration of
administration was 60 times longer. It has been reported that the
antitumour effects of cisplatin are correlated with the concentra-
tion and duration of administration (DeConti et al, 1973;
Drewinko et al, 1973); low-dose cisplatin may exhibit potent
antitumour effects.
It remains unclear whether a neutralizer sodium thiosulphate
needs to be added to such administered quantities, but we believed
that the addition of sodium thiosulphate was necessary, because
our study involved elderly patients and patients who have
malfunctioning kidneys, and also because the combined usage of
systemic chemotherapy was one of the assumptions of the study.
Regarding the radiation dosage when arterial injection chemother-
apy and radiotherapy were used concomitantly, we administered
the same doses as those that we used for cases of combined use of
systemic chemotherapy. One of our future tasks is to examine
long-term adverse effects, but no severe late-onset effects have
been observed thus far.
A randomised controlled trial was performed in the Netherlands,
comparing chemoradiation that used cisplatin as a drug agent for
arterial injection in a method similar to that of Robbins et al with
chemoradiation that used cisplatin as systemic chemotherapy.
Unfortunately, the initial outcome showed no difference between
the survival rates of the therapies. In the Netherlands study, there
were few oral cavity cancer patients (Balm and Rasch, 2006).
Although the effectiveness of chemoradiation that concomitantly
uses systemic chemotherapy has been clarified for cases of
pharyngeal and laryngeal cancer, it has not yet been clarified for
cases of oral cavity cancer. Thus, we suggest that randomised
controlled trials limit their target cases to, for example, patients
with oral cavity cancer.
The results of our study were similar to those of surgery, thus
suggesting the usefulness of arterial injection therapy combined
with radiation therapy. In particular, the results of arterial
injection therapy by cisplatin with sodium thiosulphate were
excellent, so we believe that it will be a new therapy for locally
advanced oral cavity cancer.
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